Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 5910403, 12 pages
http://dx.doi.org/10.1155/2016/5910403
Research Article

Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, Evolution, and Regulations Assessment

Institute of Innovation Based on Science, University of Talca, Avenida Lircay S/N, 3460000 Talca, Chile

Received 26 September 2015; Revised 29 February 2016; Accepted 16 March 2016

Academic Editor: Sanjay Garg

Copyright © 2016 Tomas Gabriel Bas and Carolina Oliu Castillo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. IMS Institute for Healthcare Informatics, The Global Use of Medicines: Outlook through 2017, 2013, http://www.quotidianosanita.it/allegati/allegato1501906.pdf.
  2. EvaluatePharma, “World preview 2014, outlook to 2020,” 2014, http://info.evaluategroup.com/rs/evaluatepharmaltd/images/EP240614.pdf.
  3. R. A. Rader, “(Re)defining biopharmaceutical,” Nature Biotechnology, vol. 26, no. 7, pp. 743–751, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Fuhr and E. Blackstone, “Innovation and competition: will biosimilars succeed?” Biotechnology Healthcare, vol. 9, no. 1, pp. 24–27, 2012. View at Google Scholar
  5. A. Zelenetz, I. Ahmed, E. Braud et al., “Biosimilar white paper: regulatory, scientific, and patient safety perspectives,” Journal of National Comprehensive Cancer Network, vol. 9, no. 4, pp. S1–S22, 2011. View at Google Scholar
  6. J. Sackman and M. Kuchenreuther, “The bullish outlook for bioismilars,” BioPharm International, vol. 28, no. 2, pp. 38–41, 2015. View at Google Scholar
  7. Mizuho Bank Industry Focus, Growth Requirements of the Next Generation of Industries in a Competitive Environment—Trends in the Field of Medicine, Particularly in the Pharmaceutical Field in Japan, vol. 156, 2014.
  8. EIU Japan, 2015, http://country.eiu.com/japan.
  9. Cabinet Secretariat, Japan Revitalization Strategy, Cabinet Secretariat, Cabinet Public Relations Office, 2013.
  10. S. Behme, Manufacturing of Pharmaceutical Proteins: From Technology to Economy, Wiley-VCH, Weinheim, Germany, 2009.
  11. T. Yamaguchi and T. Arato, “Quality, safety and efficacy of follow-on biologics in Japan,” Biologicals, vol. 39, no. 5, pp. 328–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Horikawa, M. Tsubouchi, and K. Kawakami, “Industry views of biosimilar development in Japan,” Health Policy, vol. 91, no. 2, pp. 189–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. L. Bennett, B. Chen, M. D. Wyatt et al., “Regulatory and clinical considerations for biosimilar oncology drugs,” The Lancet Oncology, vol. 15, no. 13, pp. e594–e605, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. “Ethical factor in the acceptability of foreign clinical data E5(R1),” in Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, February 1998, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf.
  15. Regulatory Affairs Professionals Society, RAPS, 2015, http://www.raps.org/Regulatory-Focus/News/2015/02/11/21309/Trade-Talks-Stumble-over-Biologics-Data-Exclusivity/.
  16. R. Muller, Ch. Renner, C. Gabay, G. Cassata, A. Lohri, and P. Hasler, “The advent of biosimilars: challengs and risks,” Swiss Medical Weekly, vol. 144, pp. 1–9, 2014. View at Google Scholar
  17. Generics and Biosimilars Initiative (GaBi Online), “Biosimilars Approved in Japan,” Pro Pharma Communications International, 2016, http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan.
  18. https://clinicaltrials.gov/.
  19. I. Lee and K. Bloor, “Pharmaceutical pricing policies in South Korea,” in Pharmaceutical Prices in the 21st Century, Z. Babar, Ed., pp. 151–169, Springer, 2015. View at Google Scholar
  20. http://www.biospectrumasia.com/biospectrum/analysis/189545/dong-a-pharma-diversifies-portfolio-biosimilars.
  21. S. K. Suh and Y. Park, “Regulatory guideline for biosimilar products in Korea,” Biologicals, vol. 39, no. 5, pp. 336–338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Joung, “Korean regulations for biosimilars,” Generics and Biosimilars Initiative Journal (GaBI Journal), vol. 4, no. 2, pp. 93–94, 2015. View at Publisher · View at Google Scholar
  23. MFDS, http://www.mfds.go.kr/eng/index.do?nMenuCode=5.
  24. J. Joung, Biosimilars Regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) Developments, Ministry of Food and Drug Safety, Cheongju, Republic of Korea, 2014.
  25. http://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-biosimilars-whitepaper-final.pdf.
  26. http://www.celltrion.com/en/BIO/bio02.asp?menu_num=2.
  27. http://www.mida.gov.my.
  28. http://gabi-journal.net/regulation-of-biologics-in-malaysia.html#T2.
  29. National Pharmaceutical Control Bureau. Ministry of Health. Malaysia, “Drug registration guidance document (DRGA),” 2013, http://rr.mpc.gov.my/data/lic-legal-2013-12-24-06-40-33.pdf.
  30. http://www.biotechcorp.com.my/press-release/viropro-and-oncobiologics-sign-emerging-markets-biosimilars-deal/.